000301906 001__ 301906
000301906 005__ 20250610113541.0
000301906 0247_ $$2doi$$a10.1016/j.ygyno.2025.05.013
000301906 0247_ $$2pmid$$apmid:40482607
000301906 0247_ $$2ISSN$$a0090-8258
000301906 0247_ $$2ISSN$$a1095-6859
000301906 037__ $$aDKFZ-2025-01176
000301906 041__ $$aEnglish
000301906 082__ $$a610
000301906 1001_ $$aFu, Zhuxuan$$b0
000301906 245__ $$aOvarian cancer risk and survival according to tumor sex hormone receptor expression: An ovarian Cancer association consortium and ovarian tumor tissue analysis consortium pooled analysis.
000301906 260__ $$aOrlando, Fla.$$bAcademic Press$$c2025
000301906 3367_ $$2DRIVER$$aarticle
000301906 3367_ $$2DataCite$$aOutput Types/Journal article
000301906 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1749542049_29235
000301906 3367_ $$2BibTeX$$aARTICLE
000301906 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000301906 3367_ $$00$$2EndNote$$aJournal Article
000301906 520__ $$aMany epithelial ovarian cancer (EOC) risk factors relate to sex hormones. The association between these factors and the expression of androgen receptor (AR), estrogen receptor-α (ER), and progesterone receptor (PR) in tumors is unknown.We linked epidemiologic, AR/ER/PR tumor expression, and survival data from 19 studies in the Ovarian Cancer Association Consortium (OCAC; 4762 cases, 20,888 controls) and the Ovarian Tumor Tissue Analysis (OTTA) consortium (5737 cases). We estimated odds ratios (ORs) and 95 % confidence intervals (CIs) between hormonally-linked factors and tumor AR/ER/PR expression using polytomous logistic regression. We assessed survival by AR/ER/PR tumor expression overall and by histotype using Kaplan-Meier curves and Cox proportional hazards models.Overweight/obesity was associated with higher risk of ER- tumors (OR:1.53, 95 % I:1.18-1.98). Hysterectomy was associated with greater risk of ER+ tumors (OR:4.99, 95 % CI:4.27-5.83), which varied by AR expression (Pheter=0.003). Postmenopause was associated with a higher risk of PR- tumors (OR 1.52, 95 % CI 1.26-1.83), which varied based by AR (Pheter < 0.001) and ER (Pheter < 0.001) expression. Gravidity, oral contraception duration, and breastfeeding duration showed differing dose-response relationships according to AR/ER/PR expression. Hormone therapy use, postmenopause, physical inactivity, and being obese/overweight prior to diagnosis were differentially associated with survival based on AR/ER/PR expression and histotype.EOC has varying risk and prognostic profiles depending on both histotype and AR/ER/PR expression. Biological mechanisms underlying the association between hormonally-linked factors and EOC need to be studied by both histotypes and by AR, ER, and PR expression.
000301906 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000301906 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000301906 650_7 $$2Other$$aEpithelial ovarian cancer
000301906 650_7 $$2Other$$aHormonal factors
000301906 650_7 $$2Other$$aHormone receptor
000301906 650_7 $$2Other$$aRisk
000301906 650_7 $$2Other$$aSurvival
000301906 650_7 $$2Other$$aandrogen receptor
000301906 650_7 $$2Other$$aestrogen receptor
000301906 650_7 $$2Other$$aprogesterone receptor
000301906 7001_ $$aBorho, Lauren$$b1
000301906 7001_ $$aTaylor, Sarah E$$b2
000301906 7001_ $$aKelemen, Linda E$$b3
000301906 7001_ $$aDeFazio, Anna$$b4
000301906 7001_ $$aWebb, Penelope M$$b5
000301906 7001_ $$aKöbel, Martin$$b6
000301906 7001_ $$aMeagher, Nicola S$$b7
000301906 7001_ $$aNa, Renhua$$b8
000301906 7001_ $$aAntoniou, Antonis C$$b9
000301906 7001_ $$aBrand, Alison H$$b10
000301906 7001_ $$aKennedy, Catherine J$$b11
000301906 7001_ $$aNevins, Nikilyn$$b12
000301906 7001_ $$aPharoah, Paul D P$$b13
000301906 7001_ $$aShvetsov, Yurii B$$b14
000301906 7001_ $$aWinham, Stacey J$$b15
000301906 7001_ $$aAlsop, Jennifer$$b16
000301906 7001_ $$aBeckmann, Matthias W$$b17
000301906 7001_ $$aBolithon, Adelyn$$b18
000301906 7001_ $$aBoros, Jessica$$b19
000301906 7001_ $$aBowtell, David D L$$b20
000301906 7001_ $$aBrenton, James D$$b21
000301906 7001_ $$aCarney, Michael E$$b22
000301906 7001_ $$aChudecka-Głaz, Anita$$b23
000301906 7001_ $$aCook, Linda S$$b24
000301906 7001_ $$aCybulski, Cezary$$b25
000301906 7001_ $$aFasching, Peter A$$b26
000301906 7001_ $$aFereday, Sian$$b27
000301906 7001_ $$0P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2$$aFortner, Renée T$$b28$$udkfz
000301906 7001_ $$aGarcía, María J$$b29
000301906 7001_ $$aGoode, Ellen L$$b30
000301906 7001_ $$aGoodman, Marc T$$b31
000301906 7001_ $$aGronwald, Jacek$$b32
000301906 7001_ $$aHartmann, Arndt$$b33
000301906 7001_ $$aHernandez, Brenda Y$$b34
000301906 7001_ $$aHøgdall, Estrid$$b35
000301906 7001_ $$aHuntsman, David G$$b36
000301906 7001_ $$aJensen, Allan$$b37
000301906 7001_ $$aJimenez-Linan, Mercedes$$b38
000301906 7001_ $$aJoseph, Janine M$$b39
000301906 7001_ $$aKarlan, Beth Y$$b40
000301906 7001_ $$aKaznowska, Ewa$$b41
000301906 7001_ $$aKjaer, Susanne K$$b42
000301906 7001_ $$aKluz, Tomasz$$b43
000301906 7001_ $$aKoziak, Jennifer M$$b44
000301906 7001_ $$aLester, Jenny$$b45
000301906 7001_ $$aLongacre, Teri A$$b46
000301906 7001_ $$aLycke, Maria$$b47
000301906 7001_ $$aMcGuire, Valerie$$b48
000301906 7001_ $$aMoysich, Kirsten B$$b49
000301906 7001_ $$aMurphy, Rachel A$$b50
000301906 7001_ $$aOrsulic, Sandra$$b51
000301906 7001_ $$aRamus, Susan J$$b52
000301906 7001_ $$aRodríguez-Antona, Cristina$$b53
000301906 7001_ $$aRothstein, Joseph H$$b54
000301906 7001_ $$aSamra, Spinder$$b55
000301906 7001_ $$aSieh, Weiva$$b56
000301906 7001_ $$aSteed, Helen$$b57
000301906 7001_ $$aSundfeldt, Karin$$b58
000301906 7001_ $$aTalhouk, Aline$$b59
000301906 7001_ $$aUciński, Jan$$b60
000301906 7001_ $$aWang, Chen$$b61
000301906 7001_ $$aWentzensen, Nicolas$$b62
000301906 7001_ $$aWhittemore, Alice S$$b63
000301906 7001_ $$aWilkens, Lynne R$$b64
000301906 7001_ $$aSonger, Thomas$$b65
000301906 7001_ $$aBrooks, Maria Mori$$b66
000301906 7001_ $$aTang, Lu$$b67
000301906 7001_ $$aModugno, Francesmary$$b68
000301906 773__ $$0PERI:(DE-600)1467974-7$$a10.1016/j.ygyno.2025.05.013$$gVol. 198, p. 112 - 129$$p112 - 129$$tGynecologic oncology$$v198$$x0090-8258$$y2025
000301906 909CO $$ooai:inrepo02.dkfz.de:301906$$pVDB
000301906 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2$$aDeutsches Krebsforschungszentrum$$b28$$kDKFZ
000301906 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000301906 9141_ $$y2025
000301906 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2025-01-01$$wger
000301906 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bGYNECOL ONCOL : 2022$$d2025-01-01
000301906 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-01
000301906 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-01
000301906 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2025-01-01
000301906 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2025-01-01
000301906 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-01
000301906 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2025-01-01
000301906 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-01
000301906 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2025-01-01
000301906 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-01-01
000301906 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-01
000301906 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-01
000301906 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2025-01-01
000301906 9201_ $$0I:(DE-He78)C180-20160331$$kC180$$lKrebsepidemiologie$$x0
000301906 980__ $$ajournal
000301906 980__ $$aVDB
000301906 980__ $$aI:(DE-He78)C180-20160331
000301906 980__ $$aUNRESTRICTED